Impact of Rosuvastatin Doses on LDL Levels, CPK Levels and Aspartate Aminotransferase Levels

Assessment of Impact of Rosuvastatin Doses on Low Density Lipoprotein Levels, Creatinine Phosphokinase Levels and Aspartate Aminotransferase Levels: A Randomized Controlled Trail

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06910098

Enrollment

195

Registered

2025-04-04

Start date

2023-12-01

Completion date

2024-08-31

Last updated

2025-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

LDL - Low Density Lipoprotein Receptor Disorder, Rosuvastatin

Brief summary

Particpants were divided into groups based on doses of rosuvastatin and were assessed and for CPK, LDL and AST levels

Interventions

DRUGRosuvastatin

a dose of 5mg were given and were compared for the cpk, ast and ldl levels

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

30 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

patients who were already on statins

Exclusion criteria

hereditary diseases including familial hypercholesterolemia and kidney diseases

Design outcomes

Primary

Measure	Time frame	Description
impact of rosuvstatin over LDL, CPK and AST levels	12 weeks	Pre- and post intervention levels of fasting serum low-density lipoprotein (LDL) in mg/dL were recorded and were compared in all study groups for assessment of the impact of various doses of rosuvastatin.

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026